Navigation Links
Study Finds Discontinuation of Rosiglitazone Left Many Diabetes Patients Without Good Glycemic Control
Date:4/14/2009

JACKSONVILLE, Fla., April 14 /PRNewswire-USNewswire/ -- When concerns were raised about the safety of the diabetes medication, rosiglitazone, in May 2007, many patients and their doctors made the decision to discontinue use of the drug. A study published today in Endocrine Practice by Dr. Etta Fanning from the University of Texas Health Science Center along with her colleagues reported that many patients who discontinued use of rosiglitazone received less therapy and higher blood glucose levels as a result.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090324/DC88061LOGO-b)

A meta-analysis published in 2007 showed an increased risk of cardiovascular disease and myocardial infarction for patients using rosiglitazone. After that data was published, the FDA placed a black box warning on both thiazolidinediones (TZD) on the market, rosiglitazone and pioglitazone.

The study published in Endocrine Practice today entitled Clinical Practice Impact of Rosiglitazone Discontinuation on Glycemic Control shows that 89% of patients in the study group were using combination therapy before discontinuing use of rosiglitazone. After discontinuation, only 33% of patients were on a combination therapy. Another 13% of the group were not prescribed any diabetes medication at all.

The glycemic control of the group was also impacted after discontinuing rosiglitazone. In patients who received combination therapy, and who had laboratory values in both pre- and post-discontinuation periods, significant increases were observed in both fasting blood glucose and A1c.

In an accompanying Editorial, cardiologists Drs. Stuart Zarich and Dr. Richard Nesto, from Yale Medical School and Lahey Clinic, respectively, emphasized that patients who discontinue TZD's are at risk for higher fasting blood glucose and hemoglobin A1c levels, as reported by Fanning et al, which might further their cardiovascular risk. Furthermore, they point out that 5 large prospective studies have not found that rosiglitazone has any more cardiovascular risk than placebo or other hypoglycemic drugs and that a recent meta-analysis has also shown that TZD's do not increase cardiovascular mortality.

Resources

Link to April EP issue: http://aace.metapress.com/openurl.asp?genre=issue&issn=1530-891X&volume=15&issue=3

Link to Commentary:

http://media.aace.com/images/84/Fanning weissman.pdf

Link to Editorial:

http://media.aace.com/images/84/April Ep Editorial.pdf

About Endocrine Practice

Endocrine Practice, a peer-reviewed journal published seven times a year, is the official journal of the American College of Endocrinology (ACE) and the American Association of Clinical Endocrinologists (AACE). The primary mission of Endocrine Practice is to enhance the health care of patients with endocrine diseases through continuing education of practicing endocrinologists. More information about the journal can be found at www.endocrinepractice.org.

About the American Association of Clinical Endocrinologists (AACE)

AACE is a professional medical organization with more than 6,200 members in the United States and 92 other countries. Founded in 1991, AACE is dedicated to the optimal care of patients with endocrine problems. AACE clinical endocrinologists advanced, specialized training enable them to be experts in the care of endocrine disease such as diabetes, thyroid disorders, growth hormone deficiency, osteoporosis, cholesterol disorders, hypertension and obesity. For further information about AACE, visit www.aace.com.


'/>"/>
SOURCE American Association of Clinical Endocrinologists
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Study reports success in treating a rare retinal disorder
2. Low Blood Sugar Events Increase Dementia Risk in Elderly Patients With Type 2 Diabetes, Kaiser Permanente Study Finds
3. Avoiding No Mans Land: New Deloitte Study on Follow-on Biologics Investigates Proposed Legislation and Possible Unintended Consequences
4. Impotence Drugs Dont Harm Vision: Study
5. Three Medical Centers Awarded Funds to Study Generation of Cardiac Muscle Cells
6. National Physicians Study: Nearly One Third Would Choose Different Career Today
7. Ex-White House Drug Czar McCaffrey, U.S. Congress Drug Caucus Chair Cummings, CRC Health CEO Karlin Join Hopkins Researchers at News Conference April 17 on Breakthrough Study: Internet Video Drug Treatment as Effective as Traditional Counseling
8. Study of neighborhoods points to modifiable factors, not race, in cancer disparities
9. New alternative to biopsy detects subtle changes in cancer cells, Stanford study shows
10. Study Challenges Link Between Panic Attacks, PTSD
11. Study assesses new surgical procedure for regenerating cartilage in damaged knee joints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... Coco Libre, the maker of ... Carpet Events LA GRAMMY’s Style Lounge Event. Coco Libre will offer musicians and celebrities ... before the big event. The invitation-only gifting suite, held this year at the W ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... (WaaS), today announced the integration of Clarity Intelligence Platform (CIP) into Cielo®, a ... offer real-time business intelligence (BI) to their small and medium business (SMB) clients. ...
(Date:2/12/2016)... NC (PRWEB) , ... February 12, 2016 , ... AssureVest ... surrounding areas, is initiating a charity drive that will raise funds earmarked to purchase ... John C. Tayloe Elementary School. , “My school is in a low-income area and ...
(Date:2/12/2016)... ... , ... Erlanger Agency has announced a new partnership in its ongoing community ... on the fight against breast cancer, fundraising for a local woman named Carmen, who ... Carmen is a loving single mother of two boys who also serves as caregiver ...
(Date:2/12/2016)... ... February 12, 2016 , ... Miami Dental Specialists is excited to bring patients ... office. Beginning in January, Miami Dental Specialists will offer the non-metal implants as a ... office to be chosen by the dental implant manufacturer, Straumann, to bring this cutting-edge ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 12, 2016  Apellis Pharmaceuticals, Inc., today ... million Series D preferred stock financing, co-led ... Capital Group and venBio Global Strategic Fund, ... IB Investment, and Epidarex Capital. The proceeds of ... advance clinical trials in the Company,s ongoing ...
(Date:2/11/2016)... -- - Cardiac Marker Diagnostic Testing ... Cancer Therapy. - European Point of Care Diagnostic ... - Key Diagnostic Testing Markets. - Molecular Diagnostics ... Testing. - Molecular Diagnostics in Infectious Disease Testing. ... Products World Markets. - Point of Care Diagnostic ...
(Date:2/11/2016)... INC. (NasdaqCM: PDEX) today announced financial results for its fiscal ... filed its Quarterly Report on Form 10-Q for the second ... Commission today. --> --> ... --> Net sales for the three months ended ... million from $2.8 million for the three months ended December ...
Breaking Medicine Technology: